Akebia Therapeutics (AKBA) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq set for sharp drop as Amazon, Intel amplify AI spending worries
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts AKBA Hot Sheet
Join SI Premium – FREE
Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.03), $0.01 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $49 million versus the consensus estimate of $50.93 million.
For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Why Beijing could block the SpaceX-Tesla merger
- Verra Mobility (VRRM) Tops Q3 EPS by 10c ; Offers Guidance
- Freedom Broker Upgrades Baker Hughes (BKR) to Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
